Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

Sign me up for:

This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Latest 10-K

View Latest 10-K

Stock Information

Symbol

Nasdaq: AEMD

Price

Change

Volume

52 week Low/High

Day Low/High

Company Overview

Aethlon Medical develops immunotherapeutic technologies to combat infectious disease and cancer. To augment the body's natural immune defenses, the Aethlon Hemopurifier® reduces the presence of circulating viruses in infected individuals. The technology provides a first-line candidate defense against viruses that are not addressed with proven drug therapies, including natural occurring pandemic threats and agents of bioterrorism. The Hemopurifier® can also be deployed as a strategy to improve the benefit of approved antiviral drug regimens. At present, the Hemopurifier® is being advanced in the United States under an FDA approved clinical study. Aethlon Medical is also investigating the potential use of the Hemopurifier® to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients.

Leadership

Our people are our backbone. Touting years of experience in a variety of fields, our leadership team is the source of our success.

IR Contact Information

Aethlon Medical, Inc.

11555 Sorrento Valley Road
Suite 203
San Diego, CA 92121

Investor Relations

S. A. Noonan Communications
Susan Noonan
Managing Partner
susan@sanoonan.com

Transfer Agent

Computershare Investor Services
P.O. Box 30170
College Station, TX 77842-3170
T: 781-575-2000
www.computershare.com